HER2/neu: A target for breast cancer therapy

Breast Disease

Volumn 11, Issue , 2000, Pages 7-18

  Zwick, E ^a   Wallasch, C ^a   Ullrich, A ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CISPLATIN; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GYRASE INHIBITOR; IMMUNOTOXIN; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4D5; NEU DIFFERENTIATION FACTOR; PACLITAXEL; PROTEIN BCL 2; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; CARCINOGENESIS; DRUG TARGETING; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC CODE; HORMONAL THERAPY; HUMAN; NONHUMAN; ONCOGENE NEU; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS; RAT;

EID: 0033907074     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-1999-11102     Document Type: Article

References (126)

1. Growth factor receptor tyrosine ki-nases
2. Signal transduction by receptors with tyrosine kinase activity
3. Receptor protein-tyrosine kinases and their signal transduction pathways
4. Receptor tyrosine kinases as targets for drug intervention
5. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells
6. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
7. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor
8. Isolation and characterization of ErbB-3, a third member of the ErbB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors
9. Molecular cloning and expression of an additional epidermal growth factor receptor-related gene
10. Insect cell-expressed p180erbB-3 possesses an impaired tyrosine kinase activity
11. Ligand-specific activation of HER4/p180erbB-4, a fourth member of the epidermal growth factor receptor family
12. Neu and its ligands: From an oncogene to neural factors
13. The neu oncogene: An erbB-related gene encoding a 185,000-Mr tumour antigen
14. Amplification of a novel v-erbB-related gene in a human mammary carcinoma
15. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
16. The biology of erbB-2/neu/HER-2 and its role in cancer
17. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
18. Pathologic findings from the national surgical adjuvant breast and bowel project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer
19. Monoclonal anti-body of human cancer: Taking a HER2 protooncogene to the clinic
20. Tumor targeting: Activation of pro-drugs by enzyme-monoclonal antibody
21. Tyrosine kinase inhibition: An approach to drug development
22. Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research
23. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer
24. The ErbB signaling network in embryogenensis and oncogenensis: Signal diversification through combinatorial ligand-receptor interactions
25. EGF-stimulated tyrosine phosphorylation of p185neu: A potential model for receptor interactions
26. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: A mechanism for receptor transregulation
27. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function
28. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts
29. Identification of heregulin, a specific activator of p185erbB2
30. Isolation of Neu/HER2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells
31. Neu differentiation factor: A transmembrane glycoprotein containing an EGF and immunoglobulin-homology unit
32. Cell-type specific interaction of Neu differentiation factor (NDF/Heregulin) with Neu/HER2 suggests complex ligand-receptor relationships
33. Neuregulins and their receptors: A versatile signaling module in organogenesis and oncogenesis
34. Coexpression of ErbB-2 and ErbB-3 proteins reconstitutes a high affinity receptor for heregulin
35. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3
36. Cooperative signaling of ErbB-3 and ErbB-2 in neoplastic transformation of human mammary carcinoma cells
37. Neuregulin-2, a new ligand of ErbB-3/ErbB-4-receptor tyrosine kinases
38. Ligands for ErbB-family receptors encoded by a neuregulin-like gene
39. Specificity within the EGF fam-ily/ErbB receptor family signaling network
40. Growth factor signaling by receptor tyrosine kinases
41. The SH2 and SH3 domain-containing protein GRB2 links receptor tyro-sine kinases to ras signaling
42. A novel trans-forming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction
43. Bivalence of EGF-like ligands drives the ErbB signaling network
44. ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dismerization partner
45. Differential endocytic routing of homo- and heterodimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers
46. Alternative intracellular routing of ErbB receptors may determine signaling potency
47. A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway
48. Signaling by dual specificity kinases
49. Single-chain anti-body-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling
50. Cell transformation potential of a HER2 transmembrane domain deletion mutant retained in the endoplasmic reticulum
51. The extracellular response to neuregulins is governed by complex interactions of the ErbB receptor family
52. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions
53. Distinct characteristics of heregulin signals mediated by HER3 or HER4
54. Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera
55. Morphogenetic effects of neuregulin (neu differentiation factor) in cultured epithelial cells
56. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: Implications for mammary tumors
57. Requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland
58. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase
59. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene
60. Tyrosine phosphorylation and cadherin/catenin function
61. Dominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells
62. c-erbB-2 gene product directly associates with beta-catenin and plakoglobin
63. ErbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells
64. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis in NIH 3T3 cells
65. Trans-formation of NIH 3T3 cells by overexpression of the normal coding sequence of the rat neu gene
66. Biochemical comparisons of the normal and oncogenic forms of insect cell-expressed neu tyrosine kinases
67. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: Immunohistological assessment correlates with gene amplification
68. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer
69. Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer
70. Expression of the ERBB-2 protein in benign and malignant salivary gland tumors
71. Prognostic value of c-erbB-2 protein expression in hu-man lung adenocarcinoma and squamous cell carcinoma
72. Heterogeneity of erbB-2 gene amplification in bladder cancer
73. Overexpression of the c-erbB-2 protein in human breast tumor cell lines
74. Over-expression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms
75. The neu oncogene encodes an epidermal growth factor receptor-related protein
76. Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo
77. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene
78. Induction of a variety of tumors by c-erbB-2 and clonal nature of lymphomas even with the mutated gene (Val659-Glu659)
79. Expression of the activated p185erbB-2 tyrosine kinase in human epithelial cells leads to MAP kinase activation but does not confer oncogenicity
80. Oncogenic activation of the neu-encoded receptor protein by point mutation and dele-tion
81. Novel activation mutations in the neu-proto-oncogene involved in induction of mammary tumors
82. Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation
83. Oncogenic activation of Neu/ErbB-2 in a transgenic mouse model for breast cancer
84. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation
85. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma
86. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors
87. Epidermal growth factor receptors: Critical mediators of multiple receptor pathways
88. Requirement of ErbB-2 for signalling by interleukin-6 in prostate carcinoma cells
89. Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma
90. ErbB kinases and NDF signaling in prostate cancer cells
91. Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone
92. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells
93. Follow-up study of HER-2/neu amplification in primary breast cancer
94. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer
95. Prognostic importance of c-erbB-2 expression in breast cancer. Inter Breast Cancer Study Group
96. HER-2/neu as a predictive marker of response to breast cancer therapy
97. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
98. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
99. Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells
100. Characterization of an established human, malignant, glioblastoma cell line (GMB) and its response to conventional drugs
101. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
102. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
103. Future directions of paclitaxel-based therapy of breast cancer
104. HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications
105. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
106. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing meta-static breast cancer refractory to chemotherapy treatment
107. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian can-cer cells
108. Anti-p185HER2 monoclonal antibodies: Biological properties and potential for immunotherapy
109. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
110. Putting taxanes to work in operable breast cancer: A search for selective indications from emprical studies
111. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody. A novel agent for the treatment of metastatic breast cancer
112. Recombinant anti-erbB-2 immunotoxins containing Pseudomonas exotoxin
113. Biological therapy of ovarian cancer: Current directions
114. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins
115. Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells
116. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170 (EGFR)-RTA in ovarian cancer cells
117. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: In vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models
118. Tyrphostins
119. Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins
120. Tyrosine kinase inhibitors
121. Tyrosine kinase inhibitors
122. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases
123. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog
124. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB-2, by a new class of tyrosine kinase inhibitor